Background and importance Ixekizumab and secukinumab are two monoclonal antibodies indicated in psoriasis (Ps), psoriatic arthritis (PsA) and ankylosing spondylitis in patients with inadequate response to conventional treatments by selective neutralisation of interleukin-17 (IL-17).

Aim and objectives Evaluating the persistence of IL-17 inhibitors in patients diagnosed with psoriasis and psoriatic arthritis in a reference hospital of the area.

Material and methods We made a retrospective study (May 2017 to August 2021) in which we included all patients who initiated treatment with IL-17 inhibitors. Data of sex, age, diagnostic, previous biological treatment, start date and last dispensation date were collected.

Il-17’s persistence was calculated in months using the Kaplan–Meier method and log-rank test to compare the survival along diagnostic, drug and line of treatment using SPSS Statistics, considering a p value <0.05.

Results A total of 80 patients were included (33 with ixekizumab (60% Ps, 40% PsA) and 47 with secukinumab (49% Ps, 51% PsA). 36% were men, median age 54 (IQR 42–60) years. 31.25% were treated as first line, 13.75% as second line and 55% at third line or more with a median of two previous biological drugs.

46.25% discontinued treatment during the study (60% ixekizumab, 50% secukinumab). 55% of patients had been treated for more than a year with IL-17 (35% of them for more than 2 years) and the rest 45% interrupted treatment before completing a year (58% for less than 6 months).

IL-17’s persistence was 24.1 months (95% CI 17.9 to 30.2) vs 30.9 months (95% CI 24.3 to 37.4) for ixekizumab and secukinumab, respectively, and did not show a significant difference (p=0.774).

Comparing between groups, there were no differences in ixekizumab’s persistence in Ps vs PsA (24.5 vs 14.2 months, p=0.97), secukinumab’s persistence in Ps vs PsA (32.5 vs 24.3 months, p=0.6), Ps’ persistence of ixekizumab vs secukinumab (p= 0.79) and PsA’s persistence of ixekizumab vs secukinumab (p=0.83). Regarding the persistence of the treatment line this was similar in each group, and did not show any statistical differences.

Conclusion and relevance Both IL-17 inhibitors show a similar and considerable persistence of nearby 30 months globally. No significant differences were found either between between the drugs, diagnostics nor line of treatment.

References and/or acknowledgements 1. Egeberg A. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2019;81(1):173–178.

Conflict of interest No conflict of interest